蔚藍生物(603739.SH)擬定增募資不超5億元 用於補充流動資金
格隆匯 10 月 16日丨蔚藍生物(603739.SH)披露2020年度非公開發行股票預案,擬非公開發行股票數量不超過2539.36萬股(含本數),其中西藏善誠和西藏思壯分別認購不超過1269.68萬股(含本數)、1269.68萬股(含本數),在前述認購數量上限範圍內,最終認購數量由發行人董事會及其授權人士視發行時市場情況與本次發行的保薦機構協商確定,且不超過中國證監會核准發行的股票數量。
發行對象為西藏善誠投資諮詢有限公司(“西藏善誠”)和西藏思壯投資諮詢有限公司(“西藏思壯”),以上發行對象以現金方式認購。西藏善誠和西藏思壯為公司實際控制人張效成、黃炳亮分別控制的企業,雙方以相同的價格現金認購此次發行的股票,認購的股份自發行結束之日起18個月內不得轉讓。
募集資金總額預計不超過5億元,扣除發行費用後全部用於補充公司流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.